Results 141 to 150 of about 6,510 (202)

The Impact of COVID-19 and the Practical Importance of Vaccinations and Nirmatrelvir/Ritonavir for Patients with Cardiovascular Disease. [PDF]

Vaccines (Basel)
Wełnicki M, Mamcarz A, Kuchar E, Mitkowski P, Jaroszewicz J, Tomasiewicz K, Gąsior M, Leszek P, Kamiński KA, Wysocki J.   +9 more
europepmc   +1 more source

Molnupiravir in Combination With Nirmatrelvir/Ritonavir: No Cause for Alarm. [PDF]

J Infect Dis
Kuritzkes DR.
europepmc   +1 more source

Cost-Effectiveness of Nirmatrelvir/Ritonavir in COVID-19 Patients at High-Risk for Progression in Spain. [PDF]

J Med Virol
Azanza JR, González Del Castillo JM, Ferrando R, Molero JM, Soriano A, Peral C, de Lossada A, Bellmunt A, Garí C, Mugwagwa T, López-Gómez V.   +10 more
europepmc   +1 more source

Risk Factors for Seeking Medical Care Following Nirmatrelvir-Ritonavir (Paxlovid) Treatment for COVID-19: "Symptom Rebound". [PDF]

Viruses
Bhargava A, Szpunar S, Sharma M, Saravolatz L.   +3 more
europepmc   +1 more source

Risk of Post-COVID-19 Conditions Among Adolescents and Adults Who Received Nirmatrelvir-Ritonavir for Acute COVID-19: A Retrospective Cohort Study. [PDF]

Open Forum Infect Dis
Dalton AF, Baca S, Raykin J, Gregory CO, Boehmer T, Koumans EH, Patel PR, Patel P, Saydah S.   +8 more
europepmc   +1 more source

Nirmatrelvir/ritonavir in heart transplant recipients with COVID-19: A case report on pharmaceutical care and drug interaction management. [PDF]

Medicine (Baltimore)
Zhang J, Su J, Yu X, Yue W, Chen J, Xu L.   +5 more
europepmc   +1 more source

Oral Nirmatrelvir-Ritonavir as Postexposure Prophylaxis for Covid-19. [PDF]

N Engl J Med
Hammond J, Yunis C, Fountaine RJ, Luscan G, Burr AM, Zhang W, Wisemandle W, Soares H, Baniecki ML, Hendrick VM, Kalfov V, Pypstra R, Rusnak JM.   +12 more
europepmc   +1 more source